TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05483101

Intervention type: OTHER
Intervention: Alternative birth units
Description: Midwife-led alternative birth units are a new model of care in France in which the midwife is the primary health care professional caring for low-risk pregnant women, as opposed to those cared for by an obstetrician-led medical team. Accordingly, alternative birth units also provide a space within which midwives can practice to their fullest potential with more professional autonomy than in a traditional obstetric setting. These birth units emphasizes care that promotes normal physiologic pregnancy and labor and supports the natural ability of women to experience birth with minimum or no routine intervention.~Alternative birth units named Filière physiologique (FP) co-exist in the same building on the same site as a hospital or host obstetric unit. In the event a laboring women needs comprehensive emergency obstetric care, she can be transferred immediatly in a conventionnal birth room.
Study: NCT06630585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Tirzepatide is a clear, colorless to slightly yellow solution available in cartons containing four pre-filled single-dose pens or one single-dose vial: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in a single-dose pen or vial.~In this study, the investigators will start with the recommended starting dosage of tirzepatide: 2.5 mg injected subcutaneously once weekly (for four weeks). After four weeks, the dosage will be increased to 5 mg once weekly injected subcutaneously for 12 weeks.
Study: NCT06577519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicagrel
Description: Vicagrel loading followed by Maintenance dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel loading followed by Maintenance dose
Study: NCT05843058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laughter yoga
Description: The effect of laughter yoga on psychologıcal wellness ın women wıth gynecologıcal cancer has been evaluated.
Study: NCT05261334

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: contour augmentation
Description: early implant placement with contour bone augmentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: contour augmentation
Description: early implant placement with contour bone augmentation
Study: NCT05272696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel, cisplatin and Pembrolizumab combination
Description: Pembrolizumab in combination with Nab-paclitaxel and cisplatin as induction therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Patients with PR but the maximum diameter of tumor \> 3cm or SD or PD can receive surgery directly.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemoradiotherapy
Description: After surgery, adjuvant Chemoradiotherapy or radiotherapy will be given for patients with high-risk factors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radical concurrent chemoradiotherapy
Description: Patients with PR and maximum tumor diameter ≤ 3cm or CR evaluated by MDT after 2 courses induction therapy can receive Radical concurrent chemoradiotherapy. Evaluation was performed 3 months after CRT. After MDT discussion, patients with high-risk factors need maintenance treatment.
Study: NCT06619210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL231 Dose 1/2/3/4
Description: HL231 Solution for Inhalation, dose 1/2/3 (Part A) , dose 2/4（Part B） single dose, oral inhalation by PARI BOY nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL231 Dose 1/2/3/4
Description: HL231 Solution for Inhalation, dose 1/2/3 (Part A) , dose 2/4（Part B） single dose, oral inhalation by PARI BOY nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL231 Dose 1/2/3/4
Description: HL231 Solution for Inhalation, dose 1/2/3 (Part A) , dose 2/4（Part B） single dose, oral inhalation by PARI BOY nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL231 Dose 1/2/3/4
Description: HL231 Solution for Inhalation, dose 1/2/3 (Part A) , dose 2/4（Part B） single dose, oral inhalation by PARI BOY nebulizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HL231 Dose 1/2/3/4
Description: HL231 Solution for Inhalation, dose 1/2/3 (Part A) , dose 2/4（Part B） single dose, oral inhalation by PARI BOY nebulizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HL231 Dose 1/2/3/4
Description: HL231 Solution for Inhalation, dose 1/2/3 (Part A) , dose 2/4（Part B） single dose, oral inhalation by PARI BOY nebulizer
Study: NCT04471935

Intervention type: DEVICE
Group type: OTHER
Intervention: At home Speech Hero therapy app
Description: Participants will be instructed to use the Speech Hero therapy app for three hours per week over a 4-week period.
Study: NCT05484076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breastfeeding counseling
Description: A breastfeeding booklet will be created by the researchers by taking expert opinion. This booklet will explain everything about breastfeeding in five sessions.~At 34-38 weeks of pregnancy, the first interviews will be done face-to-face at the hospital. The second interview will be made face-to-face or online, depending on the conditions, in the first 1-5 days after the birth. Subsequent interviews (postpartum 1-4 weeks, postpartum 5-12 weeks, postpartum 13-24 weeks) will be held online. The scales used in the research will be applied twice, before and after the training.
Study: NCT04972968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucocorticoid
Description: Oral Tablet
Study: NCT05524818

Intervention type: DIAGNOSTIC_TEST
Intervention: the Computerized Adaptive Testing System of the Functional Assessment of Stroke (CAT-FAS)
Description: The CAT-FAS comprises 58 items. The items were selected from four well-known physical function measures for patients with stroke: 26 items from the Fugl-Meyer Assessment-Upper Limb, 11 items from the Fugl-Meyer Assessment-Lower Limb, 12 items from the Postural Assessment Scale for Stroke Patients, and 9 items from the Barthel Index. These items evaluate motor control, postural control, and activity of daily living functions in patients with stroke. The CAT-FAS assesses all these functions simultaneously. Results are automatically reported as Rasch scores. A higher score indicates greater physical functions. In the previous study, results indicated that the CAT-FAS had sufficient efficiency (\< 10 items on average), reliability (Rasch reliability ≥ 0.88), concurrent validity (Pearson r ≥ 0.91), and responsiveness (SRM ≥ 0.65) in persons with stroke.

Intervention type: DIAGNOSTIC_TEST
Intervention: the Computerized Adaptive Testing System of the Functional Assessment of Stroke (CAT-FAS)
Description: The CAT-FAS comprises 58 items. The items were selected from four well-known physical function measures for patients with stroke: 26 items from the Fugl-Meyer Assessment-Upper Limb, 11 items from the Fugl-Meyer Assessment-Lower Limb, 12 items from the Postural Assessment Scale for Stroke Patients, and 9 items from the Barthel Index. These items evaluate motor control, postural control, and activity of daily living functions in patients with stroke. The CAT-FAS assesses all these functions simultaneously. Results are automatically reported as Rasch scores. A higher score indicates greater physical functions. In the previous study, results indicated that the CAT-FAS had sufficient efficiency (\< 10 items on average), reliability (Rasch reliability ≥ 0.88), concurrent validity (Pearson r ≥ 0.91), and responsiveness (SRM ≥ 0.65) in persons with stroke.
Study: NCT04536857

Intervention type: OTHER
Intervention: Biomarker assay
Description: Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in cerebrospinal fluid from patients with Parkinson's disease, multiple system atrophy, progressive superanuclear palsy and controls.

Intervention type: OTHER
Intervention: Biomarker assay
Description: Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in cerebrospinal fluid from patients with Parkinson's disease, multiple system atrophy, progressive superanuclear palsy and controls.

Intervention type: OTHER
Intervention: Biomarker assay
Description: Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in cerebrospinal fluid from patients with Parkinson's disease, multiple system atrophy, progressive superanuclear palsy and controls.

Intervention type: OTHER
Intervention: Biomarker assay
Description: Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in cerebrospinal fluid from patients with Parkinson's disease, multiple system atrophy, progressive superanuclear palsy and controls.
Study: NCT06008197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone
Description: Oral finerenone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo
Study: NCT06072677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program
Description: The Healthy Minds Program is a 4-week mobile program to improve coping and emotion regulation skills. It includes 4 training modules corresponding to key pillars of wellbeing: awareness(focused attention/awareness of thoughts/emotions), connection (empathy, compassion, social connection), insight (clarity of identify/experience) and purpose (applying values/motivations). The Healthy Minds Program includes 2 introductory audio lessons and guided meditations, and each 1-week module includes 2 podcast lessons (5-7 minutes) with psychoeducation and practical examples, and 3 guided meditations relevant to the module topic, for a total of 10 lessons and 14 guided meditations.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Minds Program
Description: The Healthy Minds Program is a 4-week mobile program to improve coping and emotion regulation skills. It includes 4 training modules corresponding to key pillars of wellbeing: awareness(focused attention/awareness of thoughts/emotions), connection (empathy, compassion, social connection), insight (clarity of identify/experience) and purpose (applying values/motivations). The Healthy Minds Program includes 2 introductory audio lessons and guided meditations, and each 1-week module includes 2 podcast lessons (5-7 minutes) with psychoeducation and practical examples, and 3 guided meditations relevant to the module topic, for a total of 10 lessons and 14 guided meditations.
Study: NCT05389657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based training
Description: Web-based training will be divided into training modules that will be completed by participants over the course of 6-8 weeks. Training will include didactic training videos, knowledge checks, example sessions, and a library of resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Live training
Description: The live training will be delivered by two trainers over the course of two days via Zoom.
Study: NCT05866562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Participants weighing 15 kg \< 30 kg = 300 mg Every 4 Weeks; Participants weighing 30 kg \< 60 kg = 200 mg Every 2 Weeks; Participants weighing ≥ 60 kg = 300 mg Every 2 Weeks;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants weighing 15 kg \< 30 kg Every 4 Weeks; Participants weighing 30 kg \< 60 kg Every 2 Weeks; Participants weighing ≥ 60 kg Every 2 Weeks
Study: NCT04888429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Patients received camrelizumab 200 mg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: Patients received Famitinib 20 mg once per day
Study: NCT04873453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: The current study will directly test the hypothesis that a moderate dose of CBD leads to a reduction in alcohol consumption, alcohol craving, peripheral markers of inflammation, and anxiety.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm
Study: NCT04921527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chiauranib
Description: 50mg orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50mg orally once daily
Study: NCT06081751

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pretest
Description: Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I
Study: NCT04921527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: at the first cycle, 60mg/m2, i.v infusion on day 1, 8 and 15 ; at the begining of the second cycle, after a comprehensive assessment , investigators decide whether to increase the dosage to 80mg/m2, i.v infusion on day 1, 8 and 15 ;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: at the first cycle, 60mg/m2, i.v infusion on day 1, 8 and 15 ; at the begining of the second cycle, after a comprehensive assessment , investigators decide whether to increase the dosage to 80mg/m2, i.v infusion on day 1, 8 and 15 ;
Study: NCT06160284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive a single dose of psilocybin administered in 20 mg or 25 mg doses depending on the participant's weight: 20 mg (among participants \< 70 kg) or 25 mg (among participants \>70 kg). Participants will be administered psilocybin at CNRU, within 1-2 weeks of the baseline \[11C\]-UCB-J PET.
Study: NCT06457360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: Application of sterile gauze after extraction for hemostasis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper
Description: Application of sterile gauze after extraction for hemostasis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan
Description: Application of sterile gauze after extraction for hemostasis
Study: NCT06648304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTYP01 tablets
Description: Administered 30\~60 minutes before breakfast and dinner (i.e., fasting state), bid. Subjects are given 2 tablets (60 mg) of investigational drug each time. The first administration should be administered within 1 hour after enrollment. If the subject is randomized in a fed state, the first administration may be administered in a non-fasting state. The interval between the first and second administration should be at least 6 hours, with continuous administration for 28 days (56 administrations).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Simulant TTYP01 Tablets)
Description: Administered 30\~60 minutes before breakfast and dinner (i.e., fasting state), bid. Subjects are given 2 tablets (0 mg) of placebo each time. The first administration should be administered within 1 hour after enrollment. If the subject is randomized in a fed state, the first administration may be administered in a non-fasting state. The interval between the first and second administration should be at least 6 hours, with continuous administration for 28 days (56 administrations).
Study: NCT06649526

Intervention type: OTHER
Intervention: endotracheal intubation with videolaryngoscope
Description: The present study will compare the images of two different VLs with Macintosh blades (the McGrath videolaryngoscope and the Hugemed videolaryngoscope) in both indirect (screen images) and direct (images viewed through the mouth) laryngoscopy.
Study: NCT06648616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EBT
Description: Elastic Band Resistance Training
Study: NCT06216535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram is an FDA-approved SSRI antidepressant that is administered by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive placebo comparator
Study: NCT06081751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pretest
Description: Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Posttest
Description: Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Posttest
Description: Internet usage time, How many hours do you use the Internet per day? and What is your weekly internet usage frequency? will be questioned using questions.~Child Perceived Stress Scale was developed by Snoeren-Hoefnagels (2014) and adapted to Turkish by Oral and Ersan in 2017. The scale consists of 9 items. It is a 4-point Likert type scale. It consists of a single sub-dimension. The answer never gets one point, and the answer always gets 4 points. In the scale that does not contain reverse items, the minimum score is 9 and the maximum score is 36. High scores from the scale questions mean that the individual's stress level is high.~I
Study: NCT05690789

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study: NCT05681624

Intervention type: OTHER
Group type: OTHER
Intervention: Maternal oxygen supplementation
Description: Maternal oxygen supplementation 10 liters/minute via nonrebreather mask

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Room air
Description: Room air, no mask
Study: NCT06531148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemo-mechanical caries removal
Description: Chemo-mechanical were be used as a Chemo-mechanical caries removal agent for one side of the bilateral carious teeth (selected randomly). Application of the material were be done according to the manufacturer's instructions (20). The material will be applied with a blunt spoon excavator and left for 2 minutes allowing the chemistry to work. The decayed dentin which becomes soft (due to the action of the material) was being scraped away using a blunt excavator in a pendulum movement without pressure. If necessary, the procedure will be repeated to get healthy dentin. The cavity will be visually inspected by caries detector dye to assess the complete removal of the carious dentin.

Intervention type: OTHER
Group type: OTHER
Intervention: Chemo-mechanical caries removal
Description: Chemo-mechanical were be used as a Chemo-mechanical caries removal agent for one side of the bilateral carious teeth (selected randomly). Application of the material were be done according to the manufacturer's instructions (20). The material will be applied with a blunt spoon excavator and left for 2 minutes allowing the chemistry to work. The decayed dentin which becomes soft (due to the action of the material) was being scraped away using a blunt excavator in a pendulum movement without pressure. If necessary, the procedure will be repeated to get healthy dentin. The cavity will be visually inspected by caries detector dye to assess the complete removal of the carious dentin.
Study: NCT05044975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Participants will receive sleep restriction intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Participants will receive sleep restriction intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep restriction
Description: Participants will receive sleep restriction intervention